Papillary Fissure Model Wound Healing Test – Accredited In Vivo Efficacy and Safety Evaluation for Global Markets
Our internationally accredited laboratory provides a specialist papillary fissure model wound healing test service that enables pharmaceutical developers, medical‑device manufacturers, wound‑care product formulators, tissue‑engineering companies and research institutes worldwide to quantitatively assess the efficacy, safety and mechanism of action of their therapeutic interventions in a physiologically relevant, partial‑thickness skin‑wound model. Every study is conducted under the rigorous framework of ISO/IEC 17025, and each report bearing the ILAC mark is unconditionally accepted by regulatory authorities, notified bodies and supply‑chain partners in all major economies. The papillary fissure model wound healing test precisely creates a standardised, shallow incision or a controlled dermal abrasion that extends into the papillary dermis, mimicking the common clinical presentation of a fissure, a surgical incision, or a superficial traumatic wound, and it evaluates the test article – a cream, a gel, a hydrogel dressing, a growth‑factor formulation, a skin substitute or a medical device – by measuring the wound‑closure kinetics, the histological quality of the regenerated tissue, the restoration of the dermal‑epidermal junction, the tensile strength of the healed skin, and the local inflammatory response. For a pharmaceutical company developing a recombinant growth‑factor gel for diabetic foot ulcers, a cosmetic manufacturer substantiating an “accelerates skin repair” claim, or a wound‑dressing producer obtaining a CE‑mark certification, this service delivers the legally robust, defensible in‑vivo data that underpin product registration, marketing‑claim support and the demonstration of the clinical relevance of the new therapy.
Product Samples We Regularly Subject to the Papillary Fissure Model Wound Healing Test
The animal‑surgery suite, the controlled‑environment housing, the planimetry‑imaging stations, the histopathology laboratory and the tensile‑strength testers in our facility accommodate a wide variety of wound‑healing interventions. The following categories represent the most frequently tested items:
- Topical wound‑healing creams, ointments and gels – the formulations containing the epidermal‑growth‑factor, the platelet‑derived‑growth‑factor, the hyaluronic acid, the silver‑sulfadiazine, the herbal extracts and the antimicrobial peptides
- Hydrogel, hydrocolloid, alginate and foam dressings – the primary and the secondary wound‑cover products that are applied immediately after the creation of the fissure and are changed at the defined intervals
- Amniotic‑membrane, collagen‑matrix and bio‑engineered skin substitutes – the cellular and the acellular dermal matrices, the keratinocyte‑sheets and the fibroblast‑populated scaffolds that are placed onto the wound bed
- Negative‑pressure wound‑therapy devices and the topical‑oxygen‑delivery systems – the portable and the stationary devices that apply the controlled sub‑atmospheric pressure or the humidified oxygen to the fissure wound
- Systemic and the locally injected therapeutic agents – the anti‑inflammatory drugs, the angiogenic cytokines, the stem‑cell suspensions and the gene‑therapy vectors that are administered by the subcutaneous or the intraperitoneal route
- Surgical sealants, tissue adhesives and wound‑closure strips – the cyanoacrylate glues, the fibrin sealants and the adhesive strips that are used to close the fissure and to provide the mechanical support during the healing
- Energy‑based and the physical‑therapy modalities – the low‑level laser, the ultrasound, the electrical‑stimulation and the pulsed‑electromagnetic‑field devices that are claimed to accelerate the wound repair
Creation of the Standardised Papillary Fissure Model and the Treatment Protocol
- Controlled, reproducible partial‑thickness wound induction according to the internal validated protocol: the dorsal skin of the anaesthetised Sprague‑Dawley rat or the BALB/c mouse is shaved and disinfected, and a precise, linear or a grid‑pattern incision of a defined length and depth – typically 1.5 cm long and extending through the epidermis and the papillary dermis, but not through the reticular dermis – is created using a calibrated dermatome, a micro‑scalpel or a laser‑ablation system. The depth of the wound is confirmed by the optical‑coherence‑tomography or the histological examination of a satellite group, ensuring that the model reliably reaches the papillary‑dermal level without damaging the underlying hair‑follicle stem‑cell niches. This papillary fissure model wound healing test avoids the confounding influence of the wound contraction that dominates the healing of the full‑thickness excisional wounds in the loose‑skinned rodents, and it yields the wound‑closure kinetics that are predominantly driven by the re‑epithelialisation and the granulation‑tissue formation, making it highly sensitive to the agents that promote the keratinocyte migration and the angiogenesis.
- Randomisation, blinding and the application of the test article: the animals are randomly assigned to the test‑article group, the positive‑control group (e.g., a commercially available growth‑factor gel), the vehicle‑control group and the untreated‑control group, with a minimum of ten animals per group. The test article is applied topically, injected locally or administered systemically according to the clinically relevant route immediately after the wound creation and at the pre‑determined frequency thereafter. The investigators who perform the wound‑area measurement and the histological scoring are blinded to the treatment allocation, ensuring the objectivity of the efficacy assessment.
- Post‑operative analgesia, the wound protection and the clinical monitoring: the animals receive the appropriate analgesic for the first 48 hours, and the wound is covered with a transparent, semi‑occlusive dressing that prevents the contamination and the self‑mutilation while allowing the daily inspection. The body weight, the food and the water intake, and the general clinical condition are recorded daily, and any animal that exhibits the signs of the systemic infection or the distress is excluded and reported.
Quantitative Wound‑Healing Efficacy Assessment – Planimetry, Histology and Tensile Strength According to the Internal Protocols and the Principles of ISO 10993‑6
- Digital planimetry and the wound‑closure kinetics: a calibrated digital photograph of the fissure wound is captured on the day of the surgery and on every subsequent evaluation day – typically on days 3, 5, 7, 10 and 14 – and the wound area in the square millimetres is measured by the image‑analysis software. The percentage of the wound closure relative to the initial area is calculated, and the time to the 50 % and the 100 % wound closure is determined. The wound‑closure curve and the area‑under‑the‑curve are compared between the groups by the repeated‑measures analysis of variance, providing the primary efficacy endpoint of the papillary fissure model wound healing test.
- Histological and the histomorphometric analysis of the regenerated skin according to the internal protocols and the principles of ISO 10993‑6 (Biological evaluation of medical devices – Part 6: Tests for local effects after implantation, adapted for the wound‑healing model): at the pre‑determined time‑points – typically on days 3, 7 and 14 – a subset of the animals is euthanised, and the wound tissue with a generous margin of the surrounding healthy skin is excised, fixed in the buffered formalin, embedded in the paraffin and sectioned perpendicular to the wound axis. The sections are stained with the haematoxylin‑eosin, the Masson’s trichrome and the picrosirius red, and the following parameters are semi‑quantitatively scored by a board‑certified veterinary pathologist: the degree of the re‑epithelialisation (the percentage of the original wound length that is covered by the new epithelium), the thickness of the regenerated epithelium, the number of the rete‑ridge‑like structures (the papillary projections indicating the restoration of the dermal‑epidermal junction), the granulation‑tissue maturity (the fibroblast density, the collagen‑fibre organisation and the angiogenesis), and the inflammatory‑cell infiltration (the polymorphonuclear‑leukocyte and the macrophage density). The total histological wound‑healing score is reported, and the individual parameters are compared between the groups.
- Determination of the hydroxyproline content and the collagen deposition: the wound‑tissue homogenate is hydrolysed with the hydrochloric acid, and the hydroxyproline concentration is measured by a colourimetric assay. The total collagen content in the micrograms per milligram of the dry tissue is calculated, providing the quantitative biochemical marker of the collagen synthesis that is the primary determinant of the wound‑tensile strength.
- Tensile‑strength and the wound‑breaking‑strength measurement according to the internal validated protocol: at the late time‑point – typically on day 14 or 21 – the healed wound with a strip of the adjacent skin is excised and mounted in a tensile‑testing machine, and the specimen is pulled at a constant crosshead speed until the rupture. The maximum breaking force in the newtons and the tensile strength in the megapascals are reported, and the percentage of the tensile strength of the healed wound relative to the unwounded skin of the same animal is calculated, providing the functional endpoint that directly measures the restoration of the mechanical integrity of the skin.
- Immunohistochemical and the molecular analysis of the wound‑healing markers: the tissue sections are stained with the antibodies against the Ki‑67 (the proliferating cells), the CD31 (the endothelial cells, as a marker of the angiogenesis), the α‑smooth‑muscle actin (the myofibroblasts, as a marker of the wound contraction) and the involucrin (the terminal differentiation of the keratinocytes). The number of the positive cells per unit area or the stained‑area percentage is quantified by the digital image analysis, providing the mechanistic insight into how the test article modulates the key cellular processes of the wound healing.
Inflammatory Response and Biocompatibility Assessment – Integrating the Safety Endpoints into the Papillary Fissure Model Wound Healing Test
- Local‑tissue‑reactivity scoring and the adverse‑event monitoring: the periwound skin is evaluated daily for the erythema, the oedema, the eschar formation and the exudate, using a standardised 0‑to‑4 scoring system, and any systemic adverse effect – the body‑weight loss exceeding 20 %, the behavioural change or the mortality – is documented and investigated. The test article is considered to be locally biocompatible if it does not cause a significantly higher irritation score than the vehicle control.
- Cytokine and the growth‑factor profiling in the wound‑tissue homogenate: the concentrations of the key pro‑inflammatory cytokines (the interleukin‑1β, the interleukin‑6 and the tumour‑necrosis‑factor‑α), the anti‑inflammatory cytokine (the interleukin‑10), the angiogenic factors (the vascular‑endothelial‑growth‑factor) and the fibrogenic factors (the transforming‑growth‑factor‑β1) are measured by the multiplex bead‑based immunoassay, and the pro‑inflammatory‑to‑anti‑inflammatory ratio is reported, providing the data that the risk‑assessor uses to evaluate the potential of the test article to cause an exaggerated or a prolonged inflammatory response that could delay the healing.
- Microbiological monitoring of the wound for the infection control: the wound swabs are collected at the pre‑determined intervals and plated on the selective media, and the total aerobic bacterial count and the presence of the Staphylococcus aureus and the Pseudomonas aeruginosa are reported, ensuring that the observed differences in the wound‑healing rate are not confounded by the sub‑clinical wound infection.
Report Acceptance and Global Regulatory Compliance
All investigations performed within our papillary fissure model wound healing test are executed under the fully accredited scope of our ISO/IEC 17025 quality management system. Each test report that carries the ILAC mark is therefore automatically recognised by regulatory authorities, notified bodies, customs offices and supply‑chain partners in all major economies. For pharmaceutical developers, medical‑device manufacturers, wound‑care product formulators and tissue‑engineering companies anywhere in the world, the report constitutes legally robust, internationally accepted evidence that the wound‑closure rate, the histological quality of the regenerated skin, the tensile‑strength recovery and the local‑tissue biocompatibility have been determined in accordance with the internal validated protocols and the customer‑specified methods. The documentation can be directly used to support the investigational‑new‑drug application, the CE‑marking technical file under the Medical Device Regulation, the health‑claim substantiation, the issue of inspection certificates according to EN 10204 or equivalent national standards, and the resolution of commercial and technical disputes concerning the wound‑healing efficacy and the safety of any therapeutic or cosmetic product.
